We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 75

Otsuka successful in stay application: Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd 2015 FCA 848
  • King & Wood Mallesons
  • Australia
  • August 26 2015

Further to our post of 7 July 2015, the proceedings brought by Otsuka and Bristol Myers Squibb (the "exclusive licensee" of Otsuka's patents for


Australian case notes - Odisho v Bonazzi 2014 VSCA 11
  • King & Wood Mallesons
  • Australia
  • May 20 2014

In this case the appellant, a patient who suffered a thromboembolic event following the use of tranexamic acid, claimed that her doctor had


European Commission ups the cost of paying for delay
  • King & Wood Mallesons
  • Australia, European Union, USA
  • August 13 2012

On 25 July 2012, the EC alleged that Danish pharmaceutical company Lundbeck violated EU antitrust rules by colluding to prevent other pharma companies from marketing generic versions of its best-seller antidepressant, citalopram


High Court states the obvious: AstraZeneca AB v Apotex Pty Ltd appeal decided
  • King & Wood Mallesons
  • Australia
  • September 3 2015

In a widely anticipated decision, the High Court has upheld a decision of the Full Federal Court (which was made by five, rather than the usual three


Blockbuster drug goes bust? The Federal Court finds three AstraZeneca patents relating to Crestor (rosuvastatin) invalid
  • King & Wood Mallesons
  • Australia
  • March 7 2013

In an important decision handed down on Tuesday, Justice Jagot of the Federal Court held that three patents relating to the blockbuster drug Crestor


Generic Health succeeds in invalidating patent for aripiprazole: Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 4) 2015 FCA 634
  • King & Wood Mallesons
  • Australia
  • July 7 2015

Generic Health is perhaps a step closer to bringing its generic version of the antipsychotic drug aripiprazole to market in Australia after Justice


Vision Eye Institute Ltd v Kitchen (no 2) 2015 QSC 66
  • King & Wood Mallesons
  • Australia
  • July 2 2015

In this case, the Queensland Supreme Court awarded a significant amount of damages for contingent loss of income flowing from a breach of contract


De-identification and medical records in NSW
  • King & Wood Mallesons
  • Australia
  • October 24 2014

Are health service providers in New South Wales obliged by the Health Records and Information Privacy Act 2002 (NSW) to de-identify medical records


Privacy Commissioner’s decision set aside by the Federal Court
  • King & Wood Mallesons
  • Australia
  • March 16 2015

A recent decision by Federal Court of Australia illustrated two things about privacy complaints - or at least those that end up before the courts:


Just genes? Lessons from the Myriad litigation
  • King & Wood Mallesons
  • Australia
  • August 19 2013

Last month the United States Supreme Court ruled that certain naturally occurring DNA sequences (the BRCA1 and BRCA2 genes, mutations in which are